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Cristina Iclozan,1 Yu Yu,1 Chen Liu,2 Yaming Liang,1 Tangsheng Yi,3 Claudio Anasetti,1,4
Xue-Zhong Yu1,4T helper (Th)1 cells were considered responsible for the induction of graft-versus-host disease (GVHD), but
recently the concept has been challenged. Th17 cells play a critical role in mediating autoimmune diseases, but
their role in the pathogenesis of GVHD remains unclear. Herein we compare the ability of in vitro generated
Th1 and Th17 cells from C57BL/6 mice to induce GVHD in lethally irradiated BALB/c recipients. Allogeneic
Th17 cells had superior expansion and infiltration capabilities in GVHD target organs, which correlated
with their increased pathogenicity when comparedwith naı¨ve or Th1 controls. Th17 cells caused no pathology
in the syngeneic recipients, indicating that antigen-activation was required for their pathogenicity. Polarized
Th17 cells could not maintain their phenotype in vivo as they produced a significant amount of interferon
(IFN)-g after being transplanted into allogeneic recipients; however, IFN-g was not required for Th17 cell-
induced GVHD. Further, we evaluated the pathogenesis of Th17 cells in GVHD by using polyclonal nonprimed
CD4 T cells in a clinically relevant allogeneic bone marrow transplantation (BMT) setting. We found that dis-
ruption of Th17-differentiation alone by targetingRORgt (Th17-specific transcription factor) had no significant
effect on GVHD development.We conclude that Th17 cells are sufficient but not necessary to induce GVHD.
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The therapeutic potential of allogeneic bone mar-
row transplantation (BMT) or hematopoietic cell
transplantation (HCT) offers great promise for the
treatment of various hematologic diseases. However,
graft-versus-host disease (GVHD) remains the major
complication, leading to high morbidity and mortality
of the patient [1]. Mature donor T cells recognize dis-
parate histocompatibility antigens of the recipient and
cause injuries in skin, liver, gastrointestinal epithelium,
lung, and elsewhere, initiating GVHD [2].1Immunology and Blood &Marrow Transplantation Pro-
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6/j.bbmt.2009.09.023Th17 cells are a newly identified T cell lineage that
develops via cytokine signals antagonized by products
of the Th1 (interferon [IFN]-g) and Th2 (interleukin
[IL]-4) lineages [3,4]. IL-6 and tumor growth factor
(TGF)-b induce Th17 differentiation [5-7], suggesting
a potential kinship between these inflammatory medi-
ators and regulatory T cells (Treg), which have a dis-
tinct anti-inflammatory role. TGF-b is known to
suppress Th1 and Th2 differentiation while inducing
generation of Tregs. IL-6, an inflammatory cytokine
like tumor necrosis factor (TNF)-a and IL-1, acts as
a switch upstream of TGF-b directingTh17 cell devel-
opment by its presence or permitting Treg to develop
in its absence. Blocking IL-6 signaling was recently
found to shift the balance from proinflammatory T
cells to Tregs [8]. At the transcription level, Th17 lin-
eage is uniquely regulated by RORgt and Stat3 [9-11].
How various subsets of cytokine-producing T cells
contribute to disease development is an active area in
GVHD research [12,13]. Th1 cells are considered as
the primary Th subset to induce GVHD, but Th2 cells
are also involved [14,15]. Recently, Carlson et al. [16]
reported that in vitro generated Th17 cells are able
to induce acuteGVHD (aGVHD).However, CD4 na-
ı¨ve T cells deficient for IL-17 caused ameliorated
GVHD [17], but total T cells deficient for IL-17
have caused accelerated GVHD [18]. In the current
study, we found that Th17 cells were highly
Biol Blood Marrow Transplant 16:170-178, 2010 171Polarized Th17 Cells Cause Severe GVHDpathogenic to induce GVHD, more so than naı¨ve or
Th1 controls. The high potency of Th17 cells in the
induction of GVHDwas associated with their superior
ability to expand, survive, and infiltrate in vivo. How-
ever, we provide evidence that the Th17 subset alone is
not necessary to cause GVHD.MATERIALS AND METHODS
Mice
C57BL/6 (B6, H-2b), and BALB/c (H-2d) mice
were purchased from the National Cancer Institute
(Bethesda, MD). B6 congenic Ly5.1 (H-2b), DO11.10
TCR transgenic (Tg), IFN-g KO, and RORgt KO
mice were from the Jackson Laboratory. Luciferase-
transgenic (Luc-Tg) strain on B6 background were
kindly provided byDr. R. Negrin (StanfordUniversity,
CA) [19]. All the mice used in this study were housed in
a pathogen-free facility at H. Lee Moffitt Cancer Cen-
ter & Research Institute (Tampa, FL). Experimental
procedures were reviewed and approved by the Institu-
tional Animal Care and Use Committee.
Generation of Th1 and Th17 Cells
Spleen and lymph node cells from B6 mice were
depleted of CD81 and CD251 cells with magnetic
beads. Residual CD41CD25- cells (20%-25%) were
stimulated with 2 mg/mL anti-CD3 monoclonal anti-
body (mAb) at 4 106/mL. Anti-IL-4 (10 mg/mL),
IL-12 (10 ng/mL), and IFN-g (1000 U/mL) were
added to generate Th1 cells. Anti-IL-4, anti-IFN-g
mAb, IL-6 (10 ng/mL), and TGF-b (2-5 ng/mL)
were added to generate Th17 cells. Cell culture was
split 1:2 in media with mIL-2 (50 U/mL) on day 3.
The cell phenotype was confirmed in day 4 after re-
stimulation with Phorbol 12-myristate 13-acetate 1
ionomycin for 4 to 5 hours, adding GolgiStop for the
last 2 hours. The cells were then stained for surface ex-
pression of CD4 and intracellular expression of IFN-g
and IL-17. In vitro generated Th cells were used 5 to 7
days after activation, unless specified.
Isolation of T Cells and Bone Marrow (BM) Cells
from Donor Mice
CD41 T cells were purified from pooled spleen
and lymph node cells by negative selection to remove
CD81, CD251 T cells and other non-T cells using
MACS (Miltenyi Biotec, Auburn, CA). BM was har-
vested from tibia and femurs, andT cells were depleted
through complement lysis of Thy1.21 cells.
BMTand Bioluminescent Imaging (BLI)
In myeloablative (MA) BMT models, BALB/c
mice at 8 to 10 weeks old were exposed to 800 to
900 cGy of total body irradiation (TBI). Antibioticswere added to the drinking water for the following 4
weeks. T cell-depleted BM (TCD-BM) cells alone or
in combination with purified T cells from indicated
donors were injected via the tail vein into recipients
within 24 hours after irradiation. BM cells were typi-
cally isolated from B6 Ly5.1 congenic mice, whereas
peripheral T cells were from normal B6 (Ly5.2) do-
nors, so that BM-derived T cells and peripheral T cells
can be distinguished in the recipient. Recipient mice
were monitored every other day for clinical signs of
GVHD, such as ruffled fur, hunched back, inactivity,
or diarrhea, and mortality. Animals judged to be mor-
ibund were sacrificed and counted as GVHD lethality.
In vivo BLI of BALB/c recipients transplanted with T
cells from Luc-Tg B6 donors and BM from non-Tg B6
donors was performed as described previously [20], us-
ing an IVIS200 charge-coupled device imaging system
(Xenogen, Alameda, CA).
Flow Cytometry Analysis
Multicolor flow cytometry was performed to mea-
sure the expression of surface molecules or intracellu-
lar cytokines according to standard techniques. All the
fluorescence conjugated-mAbs were purchased from
BD-Pharmingen or eBiosciences (San Diego, CA).
Cell acquisition and analysis were performed by using
a FACScan, FACSCalibur or LSR II, and CellQuest
(BD Biosciences) or FlowJo software (Tree Star,
Ashland, OR).
Histopathologic Analysis
Histopathology on small and large bowel, liver,
and lung was assessed by an expert pathologist (C.L.)
in a blinded fashion. Formalin-fixed tissues were em-
bedded in paraffin, sectioned, and stained with H&E.
The tissue sections were examined under amicroscope,
and the severity of the tissue damage was graded with
a semiquantitative scoring system. Intestinal and liver
tissues were scored for 19 to 22 different parameters
and lung tissues were scored for 6 different parameters
associated with GVHD as previously described [20].
Statistics
The log-rank test was used to detect statistical dif-
ferences in recipient survival in GVHD experiments.
Student’s t-test was used to compare percentages or
numbers of donor T cells and pathologic scores.RESULTS
In Vitro Polarized Th17 Cells Induce Severe
aGVHD in Allogeneic Recipients
To test the pathogenicity of Th1 and Th17 cells in
the induction of GVHD, we adapted previously estab-
lished protocols for in vitro generating Th1 and Th17
Figure 1. Potency and pathologic injures of Th1 and Th17 cells in GVHD induction. (A) Th1 and Th17 cells were generated from B6 naı¨ve CD41 T cells
in vitro as described in Materials and Methods. Intracellular expression of IFN-g and IL-17 on live CD41 cells is shown on Th1 and Th17 cells in day 4
after in vitro polarization. Intracellular expressions of IL-4 on both cell populations were\1% (data not shown). Lethally irradiated BALB/c (B-D) or B6
(E) recipients were transplantedwith B6 TCD-BM alone, or plus B6 CD41 naı¨ve (B), Th1 (C), or Th17 (D,E) cells as indicated. Data in graph B and E were
from 1 experiment with 5 to 6 mice per group, and data in graph C and D were pooled from 3 to 4 replicate experiments with 10 to 18 mice per group.
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conditions for 5 days, we obtained CD4 T cells that
produced IFN-g and no IL-17 or IL-4 as Th1 cells,
or produced IL-17, but no IFN-g or IL-4 as Th17 cells
(Figure 1A). The percentage of IFN-g1 and IL-171
cells typically ranged from 60% to 80% among Th1
and Th17 cells, respectively. IL-4 expression was min-
imal (\1%) for both cell types (data not shown).
To compare the ability of differentiated Th cells in
the induction of GVHD, Th1 or Th17 cells were
transplanted with TCD-BM into lethally irradiated
BALB/c recipients. Recipients of TCD-BM alone
were used as negative controls without GVHD, and
recipients of TCD-BM plus naı¨ve CD4 T cells were
used as positive controls. Potency of Th17 cells inthe induction of GVHD was assessed by titrating the
numbers of naı¨ve, Th1, and Th17 cells in allogeneic
BMT. We found that Th17 cells were at least as path-
ogenic as naı¨ve CD4 T cells, but more potent than
Th1 cells in the induction of GVHD (Figure 1B-D).
In syngeneic recipients Th17 cells failed to induce
any sign of GVHD (Figure 1E), demonstrating that
their pathogenic activity is antigen-specific.
We next studied the pathogenesis of Th17 cells in
the development of GVHD by comparing them with
Th1 cells. To evaluate the pathologic injuries in
GVHD target organs caused by Th17 or Th1 cells
in allogeneic recipients, we harvested liver, intestine,
colon, and lung tissues 2 to 3 weeks after BMT and
did the standard pathologic analysis (H&E staining).
Figure 2. Pathologic injuries caused by Th1 and Th17 cells. Lethally ir-
radiated BALB/c mice were transplanted with B6 TCD-BM alone or to-
gether with Th1 or Th17 cells (1 106 each) generated from B6 CD4 T
cells. Recipient mice were euthanized and organs were harvested 2-3
weeks after BMT. Formalin-fixed tissues were embedded in paraffin, sec-
tioned, and stained with H&E. (A) Representative micrographs are from
liver (upper), intestine (middle), and lung (lower) of BM alone, Th1, or
Th17 groups (original magnification 200). (B) Histopathology was as-
sessed by an expert pathologist in a blind fashion. The data are pooled
from 2 replicate experiments with 5 to 7 recipients per group.
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without evidence of inflammatory cell infiltration or
cellular damage in the liver, intestine, and lung. In
the recipients of BM1Th1 cells, there was minimal
portal infiltration and scattered apoptosis in the liver,
mixed inflammatory cell infiltration, apoptosis of epi-
thelial cells and crypt dropout in the intestine, and
mild perivascular infiltration in the lung. In contrast,
in the recipients of BM1Th17 cells, there was severe
inflammation, endotheliitis, and apoptosis in the liver,
overt inflammation, apoptosis and crypt dropout in the
intestine, and perivascular and peribronchial inflam-
matory infiltration in the lung (Figure 2A). Using
more quantitative analysis, we found Th17 cells gener-
ated significantly more damage in recipient lung
(P5 .02) than Th1 cells (Figure 2B).
Th17 Cells Have Superior Ability to Expand
In Vivo
To further understand the pathogenicity of Th17
versus Th1 cells in GVHD, we generated them using
naı¨ve CD4 T cells from Luc-Tg mice on a B6 back-ground [21]. TCD-BM from B6 donors were trans-
planted alone or together with luc1 Th1 or Th17
cells at 1 106 each into lethally irradiated BALB/c re-
cipients. Because 1 106 Th17 cells will induce severe
GVHD (Figure 1D), an additional group with
0.25 106 Th17 cells was included for comparison.
The end point of this experiment was to follow donor
T cell expansion and infiltration in vivo using the BLI
technology. Based on the density and distribution of
the BLI signals, Th17 cells expanded substantially
more than Th1 cells (Figure 3). Both Th1 and Th17
cells migrated in multiple target organs such as the
mouth, thymus, liver, lung, and intestines, but the
overall signal intensity of Th17 cells was significantly
higher than that of 1 106 Th1 cells (Figure 3A)
(P \ .01, at days 7 and 11). Furthermore, even
0.25 106Th17 cells generated higher signal intensity
than 1 106 Th1 cells at later time points (Figure 3B)
(P5 .005, at day 15). These data were consistent with
the potency of Th1 and Th17 cells in the induction of
GVHD (Figure 1), suggesting that the superior ability
of Th17 cells in expansion and infiltration contributes
to severe GVHD.
GVHD Induced by Th17 Cells Is Refractory to
a Treatment That Depletes Alloreactive T Cells
Our recent studies found that Th17 cells are resis-
tant to activation-induced cell death (AICD) [22]. We
further reasoned that such a resistance might not only
render Th17 cells highly pathogenic, but also result in
Th17-mediated GVHD refractory to certain treat-
ments. To test this hypothesis, we selected a treatment
with anti-CD3e F(ab0)2, which was proven to prevent
GVHD by selectively depleting alloreactive T cells
through induction of apoptosis [23]. We found that
anti-CD3-treatment effectively prevented GVHD in-
duced by Th1, but not by Th17 cells (Figure 4). Given
that we recently reported that Th17 cells were under-
going significantly less apoptosis than Th1 cells after
TCR-ligation in vivo [22], these data suggest that the
resistance of Th17 cells to AICD may contribute to
high levels of expansion and subsequently high patho-
genicity in GVHD development.
IFN-g Is Not Required for GVHD Induced by
Th17 Cells
One important question we asked was whether po-
larized Th17 cells couldmaintain their phenotype over
time. We generated antigen-specific Th1 and Th17
cells in vitro under polarizing culture condition, and
then measured their cytokine profiles upon restimula-
tion without polarizing cytokines. Under this condi-
tion, previously polarized Th17 cells produced high
levels of IL-17, but also significant amounts of IFN-g.
Conversely, previously polarized Th1 cells produced
high levels of IFN-g, but little or no IL-17 (Figure 5).
Figure 3. Expansion and accumulation of Th1 and Th17 cells in alloge-
neic recipients. Lethally irradiated BALB/c mice were transplanted with
B6 TCD-BM alone (5 106) or together with Th1 or Th17 cells in vitro
generated from naı¨ve CD4 T cells of Luc-Tg mice on B6 background.
One million Th1, Th17, or 0.25 106 Th17 cells per recipient were
transplanted. On day 4, 7, 11, and 15 after BMT recipient mice were
injected i.p. with luciferin substrate. (A) Animals were imaged from
the ventral position for quantification of donor T cells, and 2 represen-
tative mice per group are shown. (B) The average of relative signal inten-
sity of 4 to 5 mice per group, and the data represent 1 of 3 replicate
experiments.
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were less stable than that of Th1 cells. To further ad-
dress whether established Th17 cells could maintain
their phenotype in vivo, we polarized naı¨ve CD4 T
cells toward the Th17 phenotype for 2 cycles in vitro
and obtained a highly enriched IL-171 population
(.90%) with minimal contamination of IFN-g1 cells.
Those polarized Th17 cells could secrete considerable
amounts of IFN-g and TNF-a, in addition to IL-17
after in vivo transfer (Figure 6A, and data not shown).
To test whether IFN-g was also required for the effec-
tor function of Th17 cells to induce GVHD in vivo, we
compared the ability of Th17 cells generated from
WT or IFN-g KO CD4 T cells in the induction of
GVHD. As expected, most of the mice receiving
WT Th17 cells died within 60 days after BMT,
whereas 40% of the recipients of IFN-g KO Th17
cells still survived (Figure 6B). Within the experimen-
tal constraints, weight loss (Figure 6C) and survival
curves were similar after BMT with WT or KO
Th17 cells (P . .05, Figure 6B and C). These data in-
dicate that Th17 cells can produce Th1 cytokines in
addition to IL-17 (IL-171 IFN-g1TNF-a1) or redif-
ferentiate into Th1 cells without IL-17 production
(IL172 IFN-g1 TNF-a1), but IFN-g is dispensable
for the development of GVHD caused by Th17 cells.
Th17 Subset Alone Is Not Necessary for the
Development of GVHD
The results presented so far indicate that polarized
Th17 cells were highly pathogenic and sufficient to in-
duce GVHD by themselves. These studies, however,
did not reveal whether Th17-differentiation was nec-
essary for GVHD development under more patho-
physiologic situations. Therefore, we next asked
whether Th17 subset is required for the development
of GVHD. To address this question, we chose to ex-
amine whether T cells deficient for RORgt were able
to induce GVHD, because RORgt is a necessary tran-
scription factor for Th17-differentiation [9,11]. How-
ever, we found that RORgt2/2 T cells had
a comparable ability to induce GVHD (Figure 7), sug-
gesting that Th17-differentiation was not required for
GVHD development.DISCUSSION
For a long period of time, Th1 cells have been con-
sidered the most important CD4 T cell subset to
induce GVHD through inflammatory cytokines in-
cluding IFN-g and TNF-a. However, the concept
was seriously challenged by recent findings indicating
that T cells deficient for Stat4 or IFN-g caused severe
or even exacerbated GVHD [24-26]. These data were
interpreted as IFN-g promotes apoptosis of antigen
activated T cells and plays an essential role in T cell
Figure 4. Anti-CD3 treatment ameliorates GVHD induced by Th1 cells, but not by Th17 cells. Lethally irradiated BALB/c mice were transplanted with
TCD-BM alone or plus polarized Th1 (4 106/mouse) or Th17 cells (2 106/mouse) from B6 donors. Half of the recipient mice received anti-CD3
treatment (20 mg/recipient i.p. every other day starting on day 0 for 10 doses). Percentages of survival (A) and body weight change (B) are shown,
and 4 to 5 recipients were used in each group.
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demonstrate that Th1 subset is not necessary and other
Th subsets are sufficient for the GVHD induction.
Our current study unequivocally demonstrates that
Th17 subset was sufficient to induce GVHD, and fur-
thermore, Th17 cells were significantly more potent
than Th1 cells (Figures 1-2) andTh0 cells (not shown).
Preactivated T cells are known to have much reduced
ability to cause GVHD. Previous studies showed that
a large number of these T cells (ie, 10-20 106) were
required to induce lethal GVHD and our data also in-
dicated that .2 106 Th1 cells were needed to cause
lethality (Figure 1C). The evidence that 0.25 106 ac-
tivated and polarized Th17 cells were able to cause
GVHD lethality on majority of allogeneic recipients
demonstrates that Th17 subset is extremely patho-
genic (Figure 1D).
We consider that a few factors make Th17 cells
highly pathogenic. The level of Th17 cell expansion
was markedly higher than Th1 cells, supported
by stronger BLI signals in GVHD target organs
(Figure 3). The high levels of expansion for Th17 cells
could be because of faster rates of cell division and/or
less cell death. We recently reported that Th17 cells
are significantly less sensitive to AICD than Th1 cells
in allogeneic recipients because of high levels of c-
FLIP, which prevent Fas-mediated apoptosis [22].Figure 5. Stability of Th1 and Th17 phenotype after restimulation in vitro. N
peptide under polarizing conditions toward Th1 and Th17 for 4 days as describe
cells were confirmed as those in Figure 1A (data not shown). Twoweeks after p
1 106/mL were restimulated with A20, A20 pulsed with OVA peptide, or
0.5 106/mL. Culture supernatants were harvested 24 hours later andmeasure
experiments.Furthermore, Th17, but not Th1 cell-mediated
GVHD did not respond to anti-CD3-treatment (Fig-
ure 4), which depletes alloreactive T cells primarily
through induction of AICD [23]. Therefore, the
Th17 cells resistance to AICD at least partially con-
tributes to their high level of expansion and subse-
quently high pathogenicity in GVHD.
Th17 cells caused damages in overall target tissues
as severe as Th1 cells, andmore severe damage in lungs
than Th1 cells (Figure 2A and B). This finding corre-
lates with other studies showing that IFN-g-deficient
donor T cells caused augmented idiopathic pneumo-
nia syndrome [27,28]. These results are also supported
by severe lung inflammation in the transgenic mice
that overexpress IL-17A in lung epithelial cells [4],
likely by recruiting granulocytes and macrophages.
In addition to pulmonary lesions, a recent study by
Carlson et al. [16] also showed severe cutaneous pa-
thology induced by Th17 cells, which was not ob-
served in our study (not shown). We speculate that
a different GVHD model might account for the dis-
crepancy on cutaneous pathology.
Although in vitro generated Th17 cells essentially
did not produce IFN-g after polarization (Figure 1A),
the same cells could produce IFN-g upon restimula-
tion without polarizing cytokines in vitro (Figure 5)
and in vivo (Figure 6). These data suggest thataı¨ve T cells from DO11.10 TCRTg mice were activated with Ova323-339
d in Figure 1A. After polarization, phenotypes of DO11.10 Th1 and Th17
rimary stimulation, rested Th1 (empty bars) and Th17 (filled bars) cells at
OVA-transduced (low level OVA expression) A20 B cell lymphoma at
d for levels of IFN-g (A) and IL-17 (B). The data represent 1 of 2 replicate
Figure 6. Role of IFN-g in Th17 cells induced GVHD. Lethally irradiated BALB/c mice were transplanted with TCD-BM alone, or plus 2 106/mouse
Th17 cells generated fromWTmice (A), and 0.5 106/mouse Th17 cells generated fromWTor IFN-g2/2 B6mice, respectively (B,C). (A) After 22 days
intracellular expression of IL-17, IFN-g, and TNF-awere measured. %mean6 1 SD of intracellular expression of IFN-g (upper panel) and TNF-a (lower
panel) are shown together with IL-17 on donor CD41H2b1 cells from recipient spleen and liver. GVHD severity assessed by changes over time in re-
cipient survival (B) and body weight (C) is shown. Data are pooled from 2 experiments with 10 to 12 recipients per group.
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come IFN-g-producing Th1 cells and/or polarized
Th17 cells could start to produce IFN-g together
with IL-17 upon restimulation under no polarizing
conditions. Highly enriched Th17 cells after adoptive
transfer secreted considerable amounts of inflamma-
tory cytokines IFN-g and TNF-a besides IL-17 in
the recipient (Figure 6A). These data are consistent
to recent studies by others showing that in vitro polar-
ized Th17 cells have a plastic or unstable cytokine
expression profile [29,30]. Nonetheless, nonpolarized
Th0 cells (data not shown) and polarized Th1 cells
were less pathogenic than Th17 cells (Figure 1).Furthermore, Th17 cells deficient for IFN-g were still
able to induce GVHD (Figure 6B and C), demonstrat-
ing that IFN-g is not required for, although it contrib-
utes to, pathogenicity of Th17 cells. The effector
molecules responsible for Th17-mediated GVHD
are not entirely clear. Most likely, IL-17 serves as an
important effector cytokine in the development of
GVHD, because IL-17 has been shown to cause direct
tissue damages [31], and neutralizing IL-17 markedly
decreased skin and lung GVHD [16,28,32]. Polarized
Th17 cells produce significant levels of TNF-a (al-
though lower than Th1 cells) after restimulation in
vitro [33,34] as well as in vivo in allogeneic recipients
Figure 7. RORgt2/2 andWTCD4 T cells have comparable ability to induce GVHD. Lethally irradiated BALB/c mice were transplanted with TCD-BM
alone or plus purified CD41 T cells (1-2 106/mouse) isolated from WTor RORgt2/2 mice on B6 background. Percentages of survival (A) and body
weight change (B) are shown. Data cumulate 2 independent experiments with 8 to 9 mice per group.
Biol Blood Marrow Transplant 16:170-178, 2010 177Polarized Th17 Cells Cause Severe GVHD(Figure 6A). Moreover, the contribution of TNF-a in
Th17-mediated GVHD is further supported by the
observations that administration ofTNF-a antagonists
significantly reduced GVHD induced by Th17 cells
[16,28]. Finally, other cytokines produced by Th17
cells (ie, IL-21 and IL-22) may also contribute to
Th17-mediated GVHD, but direct evidence remains
to be found.
By using in vitro polarized Th17 cells, this study
and the one by Carlson et al. [16] indicate Th17 cells
are sufficient to induce GVHD, but does not exclude
that Th1 cells or their cytokines can be important ef-
fectors. Because Th17 cells produce multiple distinct
cytokines including IL-17A, IL-17F, IL-21, and IL-
22, these data do not imply that IL-17A is sufficient
or even necessary for the induction of GVHD. More-
over, these studies did not reveal whether Th17-differ-
entiation was necessary for GVHD development
under more pathophysiologic situations, because in vi-
tro polarized Th17 cells may not truly represent the
subset (ie, IL-17-producing T cells) of differentiated
from naı¨ve CD4 T cells in vivo after BMT. In further
study, we have shown that RORgt2/2 CD4 T cells
were equally able to induce GVHD as WT counter-
parts (Figure 7). These results indicate that GVHD
can occur in the absence of Th17-differentiation,
which is consistent with the findings by others that
Th1- or even Th2-subset alone is adequate to induce
GVHD [25,35]. However, Th17 cells do differentiate
from naı¨ve T cells under allogeneic BMT, and Th17
cells are highly pathogenic. Thus, high levels of
IL-17 or unbalanced T cell differentiation toward
Th17-linage may correlate with high grades of
GVHD after allogeneic HCT. Furthermore, because
Th17 cells are resistant to apoptosis [22] and Th17-in-
ducedGVHD is refractory to treatment that induces T
cell depletion (Figure 4), the current study also pro-
vides additional information to guide for the selection
of proper treatment for Th17-mediated GVHD, for
example, blocking Th17-effector function rather
than inducing apoptosis of Th17 effectors.ACKNOWLEDGMENTS
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